Post-earnings recap
Reported
Wed, Nov 6, 2019
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
63%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Nektar Therapeutics reported a wider-than-expected loss per share but did not disclose revenue figures. The stock fell by 2.37% following the report, likely due to the lack of guidance and concerns over future performance. Investors may be cautious as the company navigates its pipeline and market challenges.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.56 | N/A | +17.18% |
| Revenue | N/A | N/A | N/A |
Management expressed a cautious outlook, emphasizing the importance of their ongoing projects. They did not provide new guidance, reflecting uncertainty.
Management did not provide specific revenue guidance for the upcoming quarters.
The focus remains on advancing their pipeline despite current challenges.